{"transactions":[{"id":741341,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":6837319,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Beginning May 21, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Orphai's 2026 Stock Incentive Plan) wih the Issuer as of each such vesting date."}],"balance_after":6837319,"derivative":{"exercise_price":0.84,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":6837319},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741340,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":6837319,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":6837319,"derivative":{"exercise_price":0.84,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":6837319},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741339,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":2070107,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":2070107,"derivative":{"exercise_price":0.09,"expiration_date":"2036-03-15","underlying":"Common Stock","underlying_shares":2070107},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741338,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":133615,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":133615,"derivative":{"exercise_price":0.09,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":133615},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741337,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":362092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":362092,"derivative":{"exercise_price":0.09,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":362092},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741336,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":69350,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":69350,"derivative":{"exercise_price":0.09,"expiration_date":"2033-07-30","underlying":"Common Stock","underlying_shares":69350},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741335,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":124830,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":124830,"derivative":{"exercise_price":0.09,"expiration_date":"2032-09-05","underlying":"Common Stock","underlying_shares":124830},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741334,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":228855,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":228855,"derivative":{"exercise_price":0.09,"expiration_date":"2032-04-07","underlying":"Common Stock","underlying_shares":228855},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}},{"id":741333,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":39187,"kind":"person","name":"Roberts Brigette","position":1,"cik":"0001346566","reported_name":"Roberts Brigette","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-11T21:30:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":34675,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC (\"Orphai\") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the \"Merger Agreement\"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Orphai Holdings Therapeutics, Inc., a Delaware corporation (\"HoldCo\") and Orphai."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC (\"Orphai\") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the \"Merger Agreement\"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Orphai Holdings Therapeutics, Inc., a Delaware corporation (\"HoldCo\") and Orphai."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":34675,"derivative":{"exercise_price":0.09,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":34675},"source":{"system":"sec-edgar","filing":"0001346566-26-000004","document":"form4-06112026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346566/000134656626000004/form4-06112026_090603.xml","form_type":"4"}}]}